Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Genetic Risk Assessment for Breast Cancer

May 31st 2016

Outcomes Better With Biomarker-Based Therapies in Phase I Studies

May 19th 2016

Outcomes were significantly better in clinical trials that utilized a biomarker-based treatment selection strategy compared with non-personalized approaches.

Emerging Approaches in MDS Treatment

May 12th 2016

Rationale for Combination Therapy in MDS

May 12th 2016

Hypomethylating Agents in MDS: Factors to Consider

May 12th 2016

Treatment Goals for Higher Risk MDS

May 12th 2016

Management of Patients with MDS and Cytopenias

May 12th 2016

Options in Low-Risk Myelodysplastic Syndrome

May 12th 2016

Parameters for Blood Transfusion in MDS

May 12th 2016

Treatment Goals for Lower Risk MDS

May 12th 2016

Comorbidities, Mutations, and Risk in MDS

May 12th 2016

MDS Risk Stratification and Treatment

May 12th 2016

Diagnostic Challenges: When Is It MDS

May 12th 2016

WHO Criteria and Diagnosis in MDS

May 12th 2016

The Broad Spectrum of Myelodysplastic Syndrome

May 12th 2016

Dr. Rubin on Advantages With Whole-Exome Sequencing

April 28th 2016

Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

Precision Medicine Vital to Value-Based GI Cancer Care

April 23rd 2016

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

Genomics Studies Opening Up Fresh Options for CRC Research

April 22nd 2016

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.

The Future of Immunotherapy in HCC

April 22nd 2016

Advances in Systemic Therapy for HCC

April 22nd 2016